Shillong Herald

Microbiome Competitive Landscape Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment

 Breaking News
  • No posts were found

Microbiome Competitive Landscape Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment

May 18
03:36 2023
Microbiome Competitive Landscape Analysis, 2023 Updates  | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Microbiome Competitive Landscape constitutes key companies continuously working towards developing Microbiome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Microbiome Competitive Landscape report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Microbiome Competitive Landscape Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Microbiome Market.

 

Some of the key takeaways from the Microbiome Competitive Landscape Report:

  • Companies across the globe are diligently working toward developing novel Microbiome treatment therapies with a considerable amount of success over the years. 
  • Microbiome companies working in the treatment market are Exeliom Biosciences, MaaT Pharma, 4D Pharma PLC, Qu Biologics, Da Volterra, 4D Pharma, Finch Research and Development LLC., Rebiotix, Seres Therapeutics, AOBiome, 4D Pharma, MatriSys Biosystem, Vedanta Biosciences, AbbVie, MatriSys Bio, Evelo Biosciences, and others, are developing therapies for the Microbiome treatment 
  • Emerging Microbiome therapies such as – EXL01, MaaT 033, Thetanix, QBKPN, DAV 132, Blautix, MaaT 013, CP101, RBX 2660, SER 109, B244, Blautix, MSB-01, VE-202, ABI M201, MSB 3163, EDP1815, and others are expected to have a significant impact on the Microbiome market in the coming years.   
  • In June 2022, In order to pool their respective expertise and promote the microbiome diagnostics and therapeutics industry, Genetic Analysis AS (“GA”) and Servatus Biopharmaceuticals Ltd (“Servatus”), two microbiome DX companies, have signed a Strategic Collaboration Agreement. In the end, the partnership will combine GA’s microbiome diagnostic signature analysis with Servatus’ top-tier expertise in biotherapeutics to create new diagnostic indicators and treatment alternatives that will benefit patients all over the world
  • In June 2022, Seres Therapeutics, Inc. published confirmation data from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapy for the prevention of recurrent C. difficile infection (rCDI)
  • In July 2022, APC Microbiome Ireland, a Science Foundation Ireland (SFI) Research Centre, and Tate & Lyle, a top provider of ingredients and solutions for food and beverage production, are collaborating on a new, two-year study to better understand the effects of dietary fibres on the health of the gut microbiome
  • In October 2022, The FDA has approved for review the biologics licence application (BLA) submitted by Seres Therapeutics for SER-109, an experimental oral microbiome treatment for the reduction of recurrent Clostridium difficile infection (rCDI)
  • On 20 October 2022, Summit Therapeutics Inc. and its product candidate, ridinilazole, had an oral podium presentation at IDWeek 2022.

 

Microbiome Overview

The term “microbiome” describes a group of bacteria and how they interact with the human body. The microbiome is crucial to human physiology and disease. The numerous facets of human biology are demonstrated by the bacteria and how they interact with the human body. Numerous species, mainly bacterial and fungal ones, are found in the human body and aid in food digestion, infection control, and a host of other vital functions. Additionally, microbes can be dangerous to their human hosts.

 

Get a Free Sample PDF Report to know more about Microbiome Competitive Landscape Therapeutic Assessment-

https://www.delveinsight.com/sample-request/microbiome-competitive-landscape

 

Emerging Microbiome Drugs Under Different Phases of Clinical Development Include:

  • EXL01: Exeliom Biosciences
  • MaaT 033: MaaT Pharma
  • Thetanix: 4D Pharma PLC
  • QBKPN: Qu Biologics
  • DAV 132: Da Volterra
  • Blautix: 4D Pharma
  • MaaT 013: MaaT Pharma
  • CP101: Finch Research and Development LLC.
  • RBX 2660: Rebiotix
  • SER 109: Seres Therapeutics
  • B244: AOBiome
  • Blautix: 4D Pharma
  • MSB-01: MatriSys Biosystem
  • VE-202: Vedanta Biosciences
  • ABI M201: AbbVie
  • MSB 3163: MatriSys Bio
  • EDP1815: Evelo Biosciences

 

Microbiome Competitive Landscape Therapeutics Assessment

  • Microbiome Assessment by Product Type
  • Microbiome By Stage and Product Type
  • Microbiome Assessment by Route of Administration
  • Microbiome By Stage and Route of Administration
  • Microbiome Assessment by Molecule Type
  • Microbiome by Stage and Molecule Type

 

DelveInsight’s Microbiome Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Microbiome product details are provided in the report. Download the Microbiome Competitive Landscape report to learn more about the emerging Microbiome therapies

 

Some of the key companies in the Microbiome Therapeutics Market include:

Key companies developing therapies for Microbiome are – Seres Therapeutics, Second Genome, uBiome, Finch Therapeutics, Vedanta Biosciences, Axial Biotherapeutics, Synlogic, Evelo Biosciences, Enterome, BiomX, Microbiome Therapeutics, Rebiotix (a Ferring Company), 4D Pharma, Microbiome Insights, Azitra, DayTwo, LNC Therapeutics, Ritter Pharmaceuticals, Holobiome, Takeda (Microbiome division), and others.

 

Microbiome Competitive Landscape Analysis:

The Microbiome Competitive Landscape report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Microbiome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microbiome Treatment.
  • Microbiome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Microbiome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Microbiome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Microbiome drugs and therapies

 

Microbiome Competitive Landscape Market Drivers

  • Increasing focus on human microbiome therapeutics development, progress to personalized targeting of microbiome-based medicines are some of the important factors that are fueling the Microbiome Market.

 

Microbiome Competitive Landscape Market Barriers

  • However, hurdles in developing appropriate methods to identify, refine and test candidate therapies, high cost associated with the research and other factors are creating obstacles in the Microbiome Market growth.

 

Scope of Microbiome Competitive Landscape Drug Insight    

  • Coverage: Global
  • Key Microbiome Companies: Exeliom Biosciences, MaaT Pharma, 4D Pharma PLC, Qu Biologics, Da Volterra, 4D Pharma, Finch Research and Development LLC., Rebiotix, Seres Therapeutics, AOBiome, 4D Pharma, MatriSys Biosystem, Vedanta Biosciences, AbbVie, MatriSys Bio, Evelo Biosciences, and others
  • Key Microbiome Therapies: EXL01, MaaT 033, Thetanix, QBKPN, DAV 132, Blautix, MaaT 013, CP101, RBX 2660, SER 109, B244, Blautix, MSB-01, VE-202, ABI M201, MSB 3163, EDP1815, and others
  • Microbiome Therapeutic Assessment: Microbiome current marketed and Microbiome emerging therapies
  • Microbiome Market Dynamics: Microbiome market drivers and Microbiome market barriers 

 

Request for Sample PDF Report for Microbiome Competitive Landscape Assessment and clinical trials

 

Table of Contents

1

Microbiome Report Introduction

2

Microbiome Executive Summary

3

Microbiome Overview

4

Microbiome- Analytical Perspective In-depth Commercial Assessment

5

Microbiome Competitive Landscape Therapeutics

6

Microbiome Late Stage Products (Phase II/III)

7

Microbiome Mid Stage Products (Phase II)

8

Microbiome Early Stage Products (Phase I)

9

Microbiome Preclinical Stage Products

10

Microbiome Therapeutics Assessment

11

Microbiome Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Microbiome Key Companies

14

Microbiome Key Products

15

Microbiome Unmet Needs

16 

Microbiome Market Drivers and Barriers

17

Microbiome Future Perspectives and Conclusion

18

Microbiome Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles